---
title: "Cerus showcases INTERCEPT Blood System evidence at ISBT Congress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290052939.md"
description: "Cerus Corporation will participate in the ISBT 39th International Congress in Kuala Lumpur, Malaysia, from June 20-24, 2026. The company is scheduled to host a lunch symposium on pathogen inactivation on June 21 and present poster data regarding platelet safety, processing time, and contamination risk on June 22."
datetime: "2026-06-17T12:30:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290052939.md)
  - [en](https://longbridge.com/en/news/290052939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290052939.md)
generator: "portal-rs"
---

# Cerus showcases INTERCEPT Blood System evidence at ISBT Congress

-   Cerus will participate in the ISBT 39th International Congress in Kuala Lumpur, Malaysia, June 20-24, 2026. \* A company-sponsored lunch symposium on pathogen inactivation is scheduled for June 21, 2026. \* Cerus-related poster presentations are slated for June 22, 2026, including data on platelet safety, processing time, and contamination risk. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617460945) on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

- [Cerus Chief Legal Officer Chrystal Jensen disposes of 30,000 common shares worth $89,529](https://longbridge.com/en/news/296157496.md)
- [Cerus Q2 FY26 net loss narrows to $2.9 million; revenue rises 5% to $63.3 million](https://longbridge.com/en/news/294409500.md)
- [Invo Fertility highlights retrospective IVF platelet-rich plasma studies at Midwest Reproductive Symposium 2026](https://longbridge.com/en/news/296495699.md)
- [Enrolment concludes in Lynch’s Phase II rhPDGF-BB study](https://longbridge.com/en/news/296343171.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**